

10503930102

708010

1995年 17月 15日

1000

**FIG. 1C**

1 GGA TCC GGG ATG AAG AAC CTT TCA TTT CCC CTC CTT TTC CTT TTC TTC CTT  
     M K N L S F P L L F L F F L  
 52 GTC CCT GAA CTG CTG GGC TCC AGC ATG CCA CTG TGT CCC ATC GAT GAA GCC  
     V P E L L L G S S M P L C P I D E A  
 103 ATC GAC AAG AAG ATC AAA CAA GAC TTC AAC TCC CTG TTT CCA AAT GCA ATA  
     I D K K I R Q D F N S L F P N A I  
 154 AAG AAC ATT GGC TTA AAT TGC TGG ACA GTC TCC TCC AGA GGG AAG TTG GCC  
     K N I G L N C W T V S S R G K L A  
 205 TCC TGC CCA GAA GGC ACA GCA GTC TTG AGC TGC TCC TGT GGC TCT GCC TGT  
     S C P E G T A V L S C S C G S A C  
 256 GGC TCG TGG GAC ATT CGT GAA GAA AAA GTG TGT CAC TCC CAG TGT GCA AAG  
     G S W D I R E E K V C H C Q C A R  
 307 ATA GAC TGG ACA GCA GCC CGC TGC TGT AAG CTG CAG GTC GCT TCC TCT CTA  
     I D W T A A R C C K L Q V A S S L  
 358 GCG GGA GGG GGT GGA TGT GGG ATC GAA GGT CGC AAG CTT ACT  
     A G G G G C G I E G R K L T

FIG. 2A

1 GGA TCC GGG ATG AAG AAC CTT TCA TTT CCC CTC CTT TTC CTT TTC TTC CTT  
     M K N L S F P L L F L F F L  
 52 GTC CCT GAA CTG CTG GGC TCC AGC ATG CCA CTG TGT CCC ATC GAT GAA GCC  
     V P E L L L G S S M P L C P I D E A  
 103 ATC GAC AAG AAG ATC AAA CAA GAC TTC AAC TCC CTG TTT CCA AAT GCA ATA  
     I D K K I R Q D F N S L F P N A I  
 154 AAG AAC ATT GGC TTA AAT TGC TGG ACA GTC TCC TCC AGA GGG AAG TTG GCC  
     K N I G L N C W T V S S R G K L A  
 205 TCC TGC CCA GAA GGC ACA GCA GTC TTG AGC TGC TCC TGT GGC TCT GCC TGT  
     S C P E G T A V L S C S C G S A C  
 256 GGC TCG TGG GAC ATT CGT GAA GAA AAA GTG TGT CAC TCC CAG TGT GCA AAG  
     G S W D I R E E K V C H C Q C A R  
 307 ATA GAC TGG ACA GCA GCC CGC TGC TGT AAG CTG CAG GTC GCT TCC TCT CTA  
     I D W T A A R C C K L Q V A S S L  
 358 GCG GGA GGG GGT GGA TGT GGG GAC GAT GAC GAC AAG CTT ACT  
     A G G G G C G D D D D K L T

FIG. 2B




FIG. 2C

10050898-011802

A




FIG. 3A

B




FIG. 3B





FIG. 4A



**FIG. 4B**




FIG. 4C








FIG. 5



**FIG. 6**



**Fig 7**

FIG. 8A




FIG. 8B




FIG. 8C





FIG. 8D



1050899-01302

FIG. 9A




FIG. 9B




FIG. 10A




FIG. 10B




FIG. 11








FIG. 12



**FIG. 13A**

**FIG. 13B**

**Sulfo SMPH**






FIG. 13C

Sulfo SMPH



208TT0"9680500T

**FIG. 13D**



**FIG. 13E**




FIG. 14A




FIG. 14B






FIG. 14C




FIG. 15A




FIG. 15B





FIG. 15C



**A**




FIG. 16 A

**B**






FIG. 16 B

**FIG. 17 A**



**FIG. 17 B**

# Coupling of the murine and human VEGFR-2 peptide to Pili




FIG. 18 A



# Coupling of the murine VEGFR-2 peptide to Q $\beta$




FIG. 18 B

# Coupling of the murine VEGFR-2 peptide to cys-free HbcAg





FIG. 18 C



**FIG. 18 D**

2023-11-10 09:09:52




FIG. 18 E

10050898-011802





FIG. 18 F

10050893-011802



**FIG. 19 A**

1050808.01.1602




FIG. 19 B

Serum antibody titers in vaccinated APP23 mice





FIG. 20





**FIG. 21**

208770-96805001

Fig Qb mut S-MBS Flag




FIG. 22 A

Fig Qb mut SGMBS Flag




FIG. 22 B

Fig Qb mut SMPH Flag




FIG. 22 C



Fig Q $\beta$  mutants-PLA<sub>2</sub>-Cys

FIG. 22 D








FIG. 24



**FIG. 25 A**



2008TT0-8680500T  
10050898-011802



**FIG. 25 B**




FIG. 26






FIG. 27 A



Survival of mice vaccinated intravenously  
followed by a lethal influenza A challenge

Immunization	Survival
M2 coupled to VLP	6/6
M2 fused to VLP	0/3
Control	0/6

**FIG. 27 B**



**FIG. 28 A**




FIG. 28 B